交银国际作为联席全球协调人助力宝济药业完成港股IPO项目

交银国际
Dec 11, 2025

企业融资业务12月10日,上海宝济药业股份有限公司(“宝济药业”,2659.HK)在香港联交所主板挂牌上市。宝济药业本次全球发售定价每股26.38港元,发行37,911,700股H股,融资规模约为10.00亿港元。交银国际担任联席全球协调人、联席账簿管理人兼联席牵头经办人,全程高效助力宝济药业顺利登陆港股资本市场。宝济药业成立于2019年,战略性聚焦四大领域:(i) 大容量皮下给药,(ii) 抗体...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10